ConcertAI’s TeraRecon Offers New Suite to Eureka Clinical AI Platform
Cardio Suite to reportedly provide clinicians with artificial intelligence technology to help fight cardiovascular disease.
ConcertAI’s TeraRecon, a clinical AI SaaS company, broke the news that its Eureka Clinical AI platform's Cardio Suite now provides clinicians with the artificial intelligence and deep learning technology necessary to help identify, treat, and manage cardiovascular disease.
"The Cardio Suite represents our second installment of dedicated care area suites following the launch of the Neuro Suite earlier this year," said Dan McSweeney, President, TeraRecon. "We are committed to supporting cardiologists and clinicians by bringing novel AI powered solutions, such as our Cardio Suite, forward to more efficiently help physicians screen and diagnose cardiac disease patients so that appropriate treatments can be delivered."
Reference: ConcertAI's TeraRecon Adds Cardio Suite to its Eureka Clinical AI Platform. PR Newswire. August 30, 2023. Accessed September 5, 2023. https://www.prnewswire.com/news-releases/concertais-terarecon-adds-cardio-suite-to-its-eureka-clinical-ai-platform-301912876.html
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
